- Home
- OSUR vs SLS Comparison
OSUR vs SLS Comparison
Compare OSUR & SLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | OSUR | SLS |
|---|---|---|
| Founded | 2000 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 174.3M | 208.0M |
| IPO Year | 1986 | N/A |
Fundamental Metrics
Financial Performance| Metric | OSUR | SLS |
|---|---|---|
| Price | $2.61 | $4.15 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 2 | 1 |
| Target Price | $3.00 | ★ $7.00 |
| AVG Volume (30 Days) | 662.7K | ★ 13.8M |
| Earning Date | 02-24-2026 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $125,703,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $3.70 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $2.08 | $0.85 |
| 52 Week High | $4.22 | $5.18 |
Technical Indicators
Market Signals| Indicator | OSUR | SLS |
|---|---|---|
| Relative Strength Index (RSI) | 56.89 | 64.75 |
| Support Level | $2.43 | $3.23 |
| Resistance Level | $2.71 | $4.33 |
| Average True Range (ATR) | 0.10 | 0.61 |
| MACD | 0.03 | 0.02 |
| Stochastic Oscillator | 67.90 | 59.97 |
Price Performance
Historical ComparisonAbout OSUR OraSure Technologies Inc.
OraSure Technologies Inc is a medical devices company that develops, manufactures, and distributes oral fluid diagnostic and collection devices. Its reportable segments are diagnostics and molecular solutions. The diagnostics segment produces rapid oral diagnostic tests and specimen collection devices for infectious diseases such as HIV and HCV. The molecular solutions segment specializes in kits used to collect, stabilize, and transport genetic material samples for molecular testing of both hereditary diseases and infectious diseases, such as COVID-19. The company gets majority of its sales from the molecular solutions business, derived mainly from customers in the United States.
About SLS SELLAS Life Sciences Group Inc.
SELLAS Life Sciences Group Inc is a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications. The company's product candidates currently include galinpepimut-S, or GPS, a peptide immunotherapy directed against the Wilms tumor 1, or WT1, antigen, and GFH009, a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor.